IgG Renal Biopsy

The Genetic Renal Panel is a custom next generation targeted sequencing panel that screens 12 genes for genetic disease-drivers and risk-factors associated with thrombotic microangiopathies (TMAs) and C3 Glomerulopathy  (see background for additional information).

The MORL offers the Genetic Renal Panel which is:

  • Comprehensive – tests all genes known to be associated with a wide-array of TMAs and complement-mediated diseases
  • Easy – patient provides one blood sample
  • Convenient – blood draws are easily accessible at a patient’s local doctor’s office
  • Thorough – results are discussed at a multidisciplinary meeting in the context of your patient’s phenotype, other testing ordered and current research
  • Accurate – 99% diagnostic specificity
  • Pinpointed diagnosis – offers guidance for treatment, prognosis for transplant and genetic counseling

Methodology:
An up-to-date custom targeted genomic enrichment and massively parallel sequencing panel as well as multiplex ligation-dependent probe amplification (MLPA) makeup the Genetic Renal Panel test.

Genetic Renal Panel has a diagnostic sensitivity and specificity that is greater than 99%.

Results are discussed at a multidisciplinary Renal Group meeting.

Turnaround time:
Results are sent in approximately 3 weeks.

Sample Required:
8 - 10 cc. whole blood in lavender (EDTA) top tubes OR 10 μg DNA; minimum concentration: 50 ng/μl (A260/A280 1.8-2) resuspended in 0.1mM EDTA (10mM Tris HC1, 0.1mM EDTA, pH 8, Teknova Cat#T0220)

Cost & CPT Codes:
See the MORL testing menu

Testing Rationale:
Genetic Testing for renal disease answers many important questions pertaining to patient care. The Genetic Renal Panel provides information on recurrence chance, prognosis, and best methods of treatment.